Vor Bio’s telitacicept treatment shows significant reduction in proteinuria in adults with IgA nephropathy (IgAN) after 39 weeks, with a 55% decrease in 24-hour urine protein-to-creatinine ratio (24h-UPCR) compared to placebo. The Phase 3 clinical study in China, conducted by RemeGen Co., Ltd, achieved primary and all secondary endpoints, demonstrating deep and sustained reductions in proteinuria, stabilization of kidney function, and a favorable safety profile. Telitacicept has potential as a foundational therapy for B-cell mediated diseases. The Biologics License Application (BLA) for IgAN has been submitted in China, marking a significant milestone for telitacicept.

Read more at GlobeNewswire: Telitacicept Achieved Primary Endpoint of Reducing